{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027227","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.929344+00:00","generated_at":"2026-06-12T08:45:11.274845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4","bullets":["Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).","Cash $1.9B at June 30; $273.6M paid to GSK for excess sotrovimab supply.","Discontinued innate immunity small molecule platform to focus on antibody platform.","Phase 2 PENINSULA flu trial (VIR-2482) missed primary and secondary endpoints.","Phase 2 hep B/delta data (VIR-2218/VIR-3434) expected Q4 2023; HIV vaccine VIR-1388 Phase 1 dosing expected Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027227","json":"https://secwatch.observer/filing/0001628280-23-027227.json","markdown":"https://secwatch.observer/filing/0001628280-23-027227.md","text":"https://secwatch.observer/filing/0001628280-23-027227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/0001628280-23-027227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/vir-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:45:11.274845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}